<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14273">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02921074</url>
  </required_header>
  <id_info>
    <org_study_id>PSC-1009-16</org_study_id>
    <nct_id>NCT02921074</nct_id>
  </id_info>
  <brief_title>STATE Trial: SusTained Attention Training to Enhance Sleep</brief_title>
  <acronym>STATE</acronym>
  <official_title>STATE Trial: SusTained Attention Training to Enhance Sleep</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Posit Science Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Posit Science Corporation</source>
  <brief_summary>
    <textblock>
      This study is a validation study to document the acceptability of the Tonic and Phasic
      Alertness Training (TAPAT) training program in older adults with chronic late-life insomnia.
      The goal of this study is to employ a computerized attention-training program, TAPAT,
      designed for chronic late-life insomnia in a randomized, controlled trial to assess
      feasibility and initial efficacy in this population.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep efficiency and sleep duration scores on the Pittsburg Sleep Quality Index</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep duration obtained by actigraphy (Microsoft Band 2 watch)</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep duration obtained by sleep diary</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Insomnia</condition>
  <arm_group>
    <arm_group_label>Experimental Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Computerized plasticity-based adaptive cognitive training requiring a total maximum of 24 treatment sessions, up to 7 sessions per week, 36 minutes per session.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercially available computerized training requiring a total maximum of 24 treatment sessions, up to 7 sessions per week, 36 minutes per session.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Computerized Plasticity-Based Adaptive Cognitive Training</intervention_name>
    <arm_group_label>Experimental Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Commercially available computerized training</intervention_name>
    <arm_group_label>Active Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant must be between ages 55 and 80.

          -  Participant must meet current diagnostic criteria for Primary Insomnia Disorder based
             on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).

          -  Participant with hypertension must be undergoing treatment for this condition and on
             a stable medication regimen for hypertension for â‰¥ 8 weeks prior to screening.

          -  Participant must be a fluent English speaker

          -  Participant must have adequate visual, auditory, and motor capacity to use
             computerized intervention

          -  Participant must be willing to wear Microsoft Band 2 watch to track sleep patterns

        Exclusion Criteria:

          -  Participants with cognitive impairment, delirium or dementia, or evidence of
             cognitive impairment from a pre-existing cause.

          -  Participants with untreated psychiatric conditions, including substance
             abuse/dependence disorders, untreated obstructive sleep apnea, diagnosis of other
             sleep disorders (e.g., restless legs syndrome), recent hospitalization, ongoing
             chemotherapy or other cancer treatment, and concurrent engagement in another insomnia
             treatment.

          -  Participants enrolled in another concurrent research study.

          -  Participants who have difficulty performing assessments or comprehending or following
             spoken instructions, in the judgment of the screening clinician.

          -  Participants using computer-based cognitive training programs or has used them within
             a month of the consent date.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dana Frostig</last_name>
    <phone>(415)233-7119</phone>
    <email>dana.frostig@positscience.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sawsan Dabit</last_name>
    <phone>(415)230-3741</phone>
    <email>sawsan.dabit@positscience.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Posit Science Corporation</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Frostig</last_name>
      <phone>415-233-7119</phone>
      <email>dana.frostig@positscience.com</email>
    </contact>
    <contact_backup>
      <last_name>Sawsan Dabit</last_name>
      <phone>(415) 230-3741</phone>
      <email>sawsan.dabit@positscience.com</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas VanVleet, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael M Merzenich, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 25, 2016</lastchanged_date>
  <firstreceived_date>September 29, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
